Rolvedon

Bio & Pharma Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US

South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...

Bio & Pharma Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has ob...